| Literature DB >> 17099709 |
Shinjiro Kaneko1, Akio Iwanami, Masaya Nakamura, Akiyoshi Kishino, Kaoru Kikuchi, Shinsuke Shibata, Hirotaka J Okano, Takeshi Ikegami, Ayako Moriya, Osamu Konishi, Chikao Nakayama, Kazuo Kumagai, Toru Kimura, Yasufumi Sato, Yoshio Goshima, Masahiko Taniguchi, Mamoru Ito, Zhigang He, Yoshiaki Toyama, Hideyuki Okano.
Abstract
Axons in the adult mammalian central nervous system (CNS) exhibit little regeneration after injury. It has been suggested that several axonal growth inhibitors prevent CNS axonal regeneration. Recent research has demonstrated that semaphorin3A (Sema3A) is one of the major inhibitors of axonal regeneration. We identified a strong and selective inhibitor of Sema3A, SM-216289, from the fermentation broth of a fungal strain. To examine the effect of SM-216289 in vivo, we transected the spinal cord of adult rats and administered SM-216289 into the lesion site for 4 weeks. Rats treated with SM-216289 showed substantially enhanced regeneration and/or preservation of injured axons, robust Schwann cell-mediated myelination and axonal regeneration in the lesion site, appreciable decreases in apoptotic cell number and marked enhancement of angiogenesis, resulting in considerably better functional recovery. Thus, Sema3A is essential for the inhibition of axonal regeneration and other regenerative responses after spinal cord injury (SCI). These results support the possibility of using Sema3A inhibitors in the treatment of human SCI.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17099709 DOI： 10.1038/nm1505
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440